| S
|
| Drug |
CYP interaction |
Clinical consequences |
| salmeterol
| 3A4 : metabolism
| unlikely to be significant
|
| saquinavir (HIV PI)
| 3A4 : metabolism
| ?
|
| 3A4 : INHIBITS (less than ritonavir, indinavir)
| interaction with eg astemizole, cisapride.
|
| secobarbital (See also Barbiturates)
| 2C9 : INDUCES
| interaction potential
|
| Selective Serotonin Reuptake Inhibitors (SSRIs)
(See [Clin Pharmacokinet 1997 Dec;33(6):454-71] )
{ eg. citalopram, fluoxetine, fluvoxamine, paroxetine and sertraline }
| 2D6 : paroxetine & fluoxetine inhibit potently
| high levels of eg. perphenazine, haloperidol, thioridazine,
risperidone, tricyclics
|
| 1A2: fluvoxamine inhibits
| high levels of eg. clozapine
|
| 3A4: fluvoxamine,fluoxetine inhibit
| raised eg. alprazolam
|
| 2C19: fluvoxamine, fluoxetine inhibit
| raised eg. diazepam levels
|
| selegiline = L-deprenyl = (-)-deprenyl {MAOI}
| 2D6 : metabolism
? 2E1 {in mice, anyway}
| ?
|
| sertindole (antipsychotic)
| 2D6 : METABOLISM ; ? also 3A4
| many potential problems, as for all 2D6!
|
| sertraline
{Lowering of thioridazine concentrations poorly explained}
| CYP2C19 : METABOLISM (high affinity)
| ?
|
| 2C9 : inhibits; and metabolism (low affinity)
| ?
|
| 3A4 : (?) metabolism [Ther Drug Monit 2000 Apr;22(2):143-54]
| toxicity reported with erythromycin [Pharmacotherapy 1999 Jul;19(7):894-6]
|
| sevoflurane
| CYP2E1 : metabolism
| probably not significant (?)
|
| sildenafil
| 3A4 : substrate
(? also 2C9)
| lower doses (25mg) required if 3A4 inhibited
[Drugs 1999 Jun;57(6):967-89] eg ritonavir, saquinavir, ketoconazole, erythromycin, cimetidine;
hypotension may occur
|
| simvastatin (See also HMG Co-A reductase inhibitors)
| 3A4 METABOLISM
| rhabdomyolysis with 3A4 inhibitors
|
| sirolimus (= rapamycin)
| 3A4 : metabolism
| similar to cyclosporine (3A4)
|
| smoking (tobacco)
| CYP1A2 : INDUCES
| ?
|
| 1A1 :INDUCES (also by nicotine alone)
| ?
|
| CYP2A6 : METABOLISES nicotine (and cotinine)
| ? (note that nicotine metabolism in neonates is slow)
|
2E1 :INDUCES
[Clin Pharmacokinet 1999 Jun;36(6):425-38]
| ? (smoking has potential for interaction with
"theophylline, caffeine, tacrine, imipramine, haloperidol, pentazocine, propranolol, flecainide and estradiol")
|
| somatostatin analogues
| inhibit 3A4 and 2D6 ! [Clin Pharmacol Ther 1998 Aug;64(2):150-9]
| ?
|
| sparteine
| 2D6 : metabolism
| ?
|
| 'Statins' : see HMG Co-A reductase inhibitors
|
| SSRI antidepressants (see also Antidepressants,
and the reference above)
|
| sufentanil
| CYP3A4 : metabolism
| ?
|
| sulfamethoxazole
| 2C9 : substrate
| ?
|
| 2C9 : INHIBITS
| ?
|
| sulphaphenazole = sulfaphenazole ?!
| CYP2C19 : INHIBITS (Ki about 16 µmol)
| ?
|
| 2C9 : INHIBITS ? (0.5 µmol)
| 'clinically significant'
|
| sulfinpyrazone = sulphinpyrazone {obsolete : does anybody ever use it?}
| CYP2C9 : INHIBITS
| ?
|
| Sulphonamides (sulfonamides)
| CYP2C9 : INHIBIT
| ?
|
| suprofen {?}
| 2C9 : metabolism
| interaction potential
|